The government maintains additional points until the number of companies are more than 4, if one year has elapsed since the first generic was registered, but the number of companies with the same product is 3 or less.

Generics that are listed after one year has elapsed from the first generic registration date are not added.

First of all, Myungin Acamprosate 333mg Tablet is increased by 11.1% from ￦135 to ￦150.

Whanin Acamprosate Tablet also rises 30.4% from ￦135 to ￦176.

On the other hand, Roche's Herceptin 150mg (Trastuzumab) falls 8.1% from ￦394,298 to ￦362,340 after the addition period ends.

When the generic is registered, the government directly regulates the upper limit of the first listed product and the product with the same administration route, ingredients, and formulation as the first listed product.

In addition, for the first year from the date the first generic was registered, the first listed product is added (or maintained) at 70%, and then the additional point is ended.

However, even if one year has elapsed, if the number of companies with the same product is 3 or less, the addition is maintained until 4 or more.

First, among the 23 items falling by the authority adjustment, Tronain cream 450g dropped by 12% from ￦22,500 to ￦19,800, and JW shinyak's Panaderm cream fell by 18.5% from ￦24,300 to ￦19,800.

Nelson's Bedestar cream 450g fell 25.4% from ￦26,550 to ￦19,800, Bedestar cream 30g from ￦1,770 to ￦1,320, and Ahn-gook's Saerogenta cream from ￦26,550 to ￦19,800.

CJ Healthcare’s Almarl 10mg tablet (Arotinolol HCl) from ￦320 to ￦280 from April 1st, Almarl 5mg from ￦207 to ￦182, 12.5% and 12.1%, respectively, will be reduced.

As of March 1, next year, the addition will be over and Almarl 10mg will be dropped by ￦214 and Almarl 5mg will be dropped by 23.6% to ￦139 again.

As of April 1, Hanmi Urea cream 50g fell from ￦2,495 to ￦2,157, and Hanmi Urea cream 450g from ￦22,472 to ￦19,412, by 13.5% and 13.6% respectively.

It is lowered by adjustment, as of March 1, next year, Hanmi Urea cream 50g will be dropped from ￦2,157 to ￦1,650 again, and Hanmi Urea cream 450g will be dropped from ￦19,412 to ￦14,850, by 23.5%.

◆Voluntary price cut = 9 items in which the drug price goes down by the company itself.

The government lowers the price by calculating the amount of the application if a manufacturer, consignment manufacturer, seller or importer applies for a lower price at an amount lower than the upper limit of the drug registered in the company's circumstances such as marketing or market share

For the item, Synagis 50mg will be cut from ￦541,531 to ￦536,116.

Synagis 100mg drops from ￦932,996 to ￦923,666 respectively.

Hyundai's Uremin 0.1mg (Desmopressin acetate) falls 0.8% from ￦735 to ￦729, and Uremin 0.2mg falls 0.5% from ￦1,136 to ￦1,130.

The government has designated drugs that are essential for patient care, but do not have payability, so manufacturers, consignment manufacturers, and importers avoid production or imports and require production or import cost preservation as shortage prevention drugs to conserve costs.

Shortage prevention drugs are determined in accordance with the criteria such as: ▲Designation of cost preservation ▲ Adjustment of the upper limit of production cost preservation items ▲ Designation of cost preservation and adjustment of upper limit.

First, the production cost preservation items are SK Plasma’s Hepabulin SN (for intravenous　hepatitis B human immunoglobulin) and Hepabig inj by Green Cross (for intravenous hepatitis B human immunoglobulin).

There are two drugs that raise the upper limit as a production cost preservation item.

Celltrion Oxymetholone’s price is raised 20.7% from ￦588 to ￦710 next month.

Yuyu ‘s Lincocin 500mg capsule (Lincomycin HCl) will be increased by 13.6% from ￦184 to ￦209.

Some drugs are designated as cost-preserving products and have an upper limit.

Bukwang's Holoxan 1000mg (Ifosfamide) is raised by 28.5% from ￦12,275 to ￦ 15,779.